Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418262 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
A Phase 3 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT00418262 is a Phase 3 study that has completed, run by University of Oklahoma. The registered enrollment target is 27 participants.
The verdict
NCT00418262, a Phase 3 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
Determine if atomoxetine is safe and well tolerated by children with fetal alcohol syndrome.
Interventions
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2005-08 |
| Est. Completion | 2015-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00418262
The ClinicalTrials.gov registry entry for NCT00418262 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine is the first listed.
NCT00418262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00418262 about?
NCT00418262 is a clinical study titled "Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD". Determine if atomoxetine is safe and well tolerated by children with fetal alcohol syndrome.
What is the current status of trial NCT00418262?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2005-08. Estimated completion is 2015-04-22.
What interventions are being tested in trial NCT00418262?
The interventions under investigation include: Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00418262?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.